- MACD is crossing MACD signal line at 0.1. MACD crossing signal line is bullish signal.
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Beigene stock broke out and surged to a record high Thursday after China's regulators approved its lung cancer treatment. Earlier this week, Novartis signed on to commercialize the drug.
Merck's (MRK) investigational 15-valent pneumococcal conjugate vaccine, V114 includes pneumococcal serotypes 22F and 33F, which are not included in the currently licensed conjugate vaccines.
The drugmaker expects its current pipeline of drugs could generate $25 billion in annual revenue and sees opportunities for more acquisitions.
Moderna Inc's (NASDAQ: MRNA) coronavirus vaccine candidate mRNA-1273 gained another regulatory approval Tuesday. Separately, the company also announced a high-profile executive appointment.Sixth Approval Secured: Cambridge, Massachusetts-based Moderna said Tuesday that Swissmedic, the Swiss Agency for Therapeutic Products, has authorized its vaccine in Switzerland.The authorization was issued according to the "ordinary approvals" procedure, and was based on a rolling submission of data and the...
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 11) * 10X Genomics Inc (NASDAQ: TXG) * AbbVie Inc (NYSE: (ABBV) * Aldeyra Therapeutics Inc (NASDAQ: ALDX) * Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) * AtriCure Inc. (NASDAQ: ATRC) (reacted to the company's preliminary fourth-quarter results) * Bioanalytical Systems, Inc. (NASDAQ: BASI) * Biodesix Inc (NASDAQ: BDSX) * C4 Therapeutics Inc (NASDAQ: C...
US FDA Accepts for Priority Review the Biologics License Application for V114 for Use in Adults 18 Years of Age and Older
Sanofi's (SNY) potential acquisition of Kymab, a private biotech, is set to strengthen its presence in immunology.
The Zacks Analyst Blog Highlights: Coca-Cola, Merck, Royal Dutch Shell, Gilead Sciences and FedEx